Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
djp,
or anyone else know if the KARGER article is bona-fide 'peer reviewed' article?
gh
I imagine that there would be dozens, if not hundreds, of outstanding eminently qualified candidates for the positions on the BOD who would jump at the chance to participate in this history making company.
I'd bet Leo has lots of them in mind!
I trust Leo to choose wisely.
gch
Someone please correct me if I'm wrong--
If/when Brilacidin is approved after the upcoming phase III trial for ABSSSI, it could then be prescribed OFF LABEL for other infections at the discretion of an individual doctor or hospital.
I invite discussion of the medical and financial repercussions.
If Barry starts picking winners and losers, we're screwed.
I just posted to SA:
Thanks Karin; nice piece.
You didn't want to mention it but I will: there will be a presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held in Copenhagen, Denmark from April 25-28, 2015. ECCMID is one of the largest annual gatherings of infectious disease experts in the world, and an ideal forum to present the results of a clinical trial.
This will be the first presentation to a MEDICAL audience to report on the recently completed phase 2b clinical trial of Brilacidin. There should be lots of new eyes of people with insight and money to invest. Shorts beware!
gcharvey
These listed implants (catheters, breast implants, and pacemakers) are RELATIVELY easy to re-do if infected, Try to imagine the psychic toll of having to undergo the re-doing an infected hip implant!
gh
I don't know why its not a sticky yet, but I got my issue of TIME in the mail. According to Wikipedia, 3.2 million copies are distributed so there could be lots of new eyes on AEMD on Monday!
gh
These bureaucrats make me sick!
We've had a safe and effective treatment for years. FDA sees their job as protecting the big Pharma companies. Shut up and get out of the way!
We know the HP is safe (see India)
Now just try it in some otherwise hopeless victims in Africa,
NOW!
FDA blocks devices too.
I own 2 device companies; one is an ultrasound device to treat prostate cancer without surgery (approved, and used safely in Europe for years). The other is the Hemopurifier,a blood filter that removes virus and other particles safely. Endless red tape and roadblocks from FDA. Infuriating.
gh
I have just emailed Mr. Aruda:
Mr. Aruda,
Congratulations for your recent settlement with regard to Kevetrin.
I am a small investor in CTIX and am envious of your newly acquired position. As a shareholder, I would be appreciative of any input you might have to a very active message board at Investor's Hub, where many other shareholders participate: http://investorshub.advfn.com/Cellceutix-Corporation-CTIX-12580/. Of course, I understand if there is a confidentiality agreement in place.
The market seems to have taken the news of the settlement in stride so far, and I wish for all of us invested in CTIX to experience significant gains as Kevetrin and our other drugs continue in their respective trials.
Once again, congratulations,
George Harvey
I'm askin' everybody.
gh
I've heard 'CELLCEUTIX' pronounced in several audio clips, but I have never heard 'Thioureidobutyronitrile' pronounced anywhere. I pledge $20.00 to the charity of your choice to the first person who posts the URL where I can hear the chemical name of 'Kevetrin' in an audio clip. :)
gh
He's a GIANT !!!
GH
Thank You ASPIRE!
Some here have complained about the apparent selling by Aspire tending to keep the price of CTIX down. I see the role of Aspire as a benefit to both Aspire and CTIX. They benefit by the arrangement and by selling most of the shares put to them at a small profit. Shareholders benefit by having a solid base of value in the marketplace. When the overwhelming cascade of clinical results makes it clear that the market value of CTIX has been held down by Aspire selling, the true value and price of CTIX will be significantly adjusted, making all longs very well rewarded. Aspire too will gain, because being perhaps the most interested company other than CTIX, will have held a large position in its own portfolio.
Thank You Aspire, for giving CTIX the liquidity it requires and us, the shareholders, time to accumulate our long positions at reasonable (low) prices.
gh
I just posted this as a comment to the WIRED article:
There is a new drug in trials now, Brilacidin, with results due in the next few weeks or months. Its a new class of drug called a defensin-mimetic. Here's a link to a recent press release: http://cellceutix.com/cellceutix-brilacidin-absssi-trial-gets-positive-review-by-data-safety-monitoring-board-best-possible-outcome-no-treatment-related-serious-adverse-events-saes/#sthash.Ss5BcKxl.bsMVKpUT.dpbs
The company, Cellceutix (CTIX) also has a cancer drug in trials at Harvard's Dana Farber Cancer Institute and a promising pipeline of other drugs.
Disclosure: I own stock in CTIX.
I'd like a 3-5 minute video tour, with a polished, informative narration, as long as no secret stuff is revealed.
gh
I just had to share this!
http://www.sciencedaily.com/videos/42ab8dc402624c8a971068fd3b6a10fd.htm
gh
POPULAR SCIENCE ARTICLE
http://www.popsci.com/article/science/age-antibiotics-over
I emailed to the author, Brooke Borel the following:
Brooke,
Thanks for the article on antibiotics in Popular Science.
Clearly we have used and overused our current arsenal to the point of exhaustion and new thinking must come into play if we are to continue to be safe from the deadly scourge of evolving bacteria. Let me bring to your attention a drug in trials now, Brilacidin, a new class of drug called a defensin-mimetic.
I own stock in the company, Cellceutix, CTIX, that has Brilacidin in trials, and is about to announce results in the next several weeks or months. Here is a link to the company webpage that can explain it better than I. http://cellceutix.com/brilacidin/#sthash.seNp1mfS.dpbs
Cellceutix has another drug, Kevetrin, for cancer, in trials at Harvard's Dana-Farber and Beth Israel Cancer Centers, another potential blockbuster.
In my opinion, CTIX is drastically undervalued.
Thanks again,
George Harvey
THANKS JB
Ellaruth's SA article is welcome and interesting. In my opinion, she seriously underestimates the deal making possibilities for Leo. She mentions $250M and a 4% royalty for ALL of the Poly pipeline. I would think $400M and a 25% royalty for JUST Brilacidin might be closer to reality. Otherwise, they can go pound sand. There are other drugs there that nobody can possibly place a value on without more lab and clinical work.
I trust Leo's judgement on these maters, not Ellaruth's. Nonetheless, I am thankful and happy that the subject of deal making is being discussed.
gh
LOTS OF PARTIES !!!
ITS NOT FAIR
3 days old and he already has more hair than I do!
gh
I just posted this in response to a FORBES article by Matthew Herper: How To Avert An Antibiotic Apocalypse.
http://www.forbes.com/sites/matthewherper/2014/01/27/how-to-avert-antibiotic-apocalypse/
Full disclosure: I am long Cellceutix (CTIX), a very small cap company-under $200 Million and stock price under $2.00. They have a very promising antibiotic, brilacidin, in human trials now, set to report results in a couple of months. Here’s a recent press release that explains it better than I can. CTIX also has a cancer drug in trials at Harvard’s Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. https://finance.yahoo.com/news/cellceutix-brilacidin-absssi-trial-gets-110000777.html
This is such a small company that its under the radar and so has the potential to be a life changing investment. The several drugs in their pipeline have the potential to save lives. I’d be happy to read your comments on CTIX.
Thanks for your interesting article.
George Harvey
Its NOT Leo keeping shareholders in the dark.
DF is doing, and paying for the trial of K; with CTIX just supplying the K. DF is spending their $$$ and its their show; results are released, or not, on their schedule. It appears that DF is doing a meticulous job and wants flawless execution for this presumably earth shattering product. We expect no less from Harvard.
Remember, the longer we go without reaching MTD, the less toxic,and thus more valuable K will be. Waiting gives us all more time to accumulate more inexpensive shares; it does not reduce confidence in the ultimate success of the trial.
I don't want Leo, or anyone, to prematurely rock the boat by leaking confidential information.
I plan on adding to my holdings as my finances permit, and not selling until I have life changing profits.
gh
Thanks philife,
I always thought that the Homeland Security categorization was derived from the days of the DARPA and BARDA (?) contract.
With a more accurate category, we might get a few more new eyes on our potentially significant technology.
gh
Why are we categorized as a 'Homeland Security' company and not as a 'medical equipment' company.
Can one of our moderators change this?
Thanks,
gh
I just emailed to the author of the article, James Grundvig, thanking him for his interesting piece. I also directed him to our IHUB forum.
gh
Here's Patrick's latest. I just got it via email. Touts his expensive newsletter. Strong on BioTime and several others:
http://www.mauldineconomics.com/landing/the-curse-of-the-alchemist
gh
I think if Dr. Jerry had called it a PRIVATE rather than a secret meeting, his meaning would have been similar but more believable and less prone to excessive criticism. I'm sure there could have been hundreds if not thousands of private meetings at ASCO.
gh
What you might learn from such posts
is that, if he posts 20 such posts a day, you can make a judgement about his mindset and add sufficient pinches of salt. If over time there are only 2 such posts per day, he may be less fervent in his disdain. Then if he stops posting or changes to a positive outlook, you may see the negative influence of his rantings wane, underscoring a rise in the value of your holdings.
gh
Don't ignore the naysayers, learn from them.
I try to take EVERYONE'S posts with a grain (or more) of salt. I've been long for several years and am still underwater. I still want to know what all the posters are thinking and doing. If, as I hope, the company prospers, those naysayers may turn positive or just stop their negativity. Either way, I want to get all the information I can from anyone who's paying attention.
gh
My 67 year old memory is not perfect
But I remember Leo answering a question, whether CTIX would be at ASCO again this year, in the affirmative. We can't present about an ongoing K trial, but he and others sure could attend and keep interest high with those who may be considering future possibilities for K and our great other sweepstakes entries.
I trust Leo and the other CTIX medical and management personnel to drive a hard bargain. Being the largest shareholders, he and Dr. M. have the most to gain from a great deal. We other shareholders are truly fortunate to be along for the ride of a lifetime. Waiting is excruciating (and entertaining ), but will make victory all the sweeter.
gh
Doc.S. should stay away from the Amsterdam RED Light district. You never know what kind of VIRUS you might pick up. :)
Sent to Leo at 12:54
New shortcut in UK
Maybe we don't need to wait for DF for CTIX to move forward. I saw reference to this on another IHUB board: http://www.mhra.gov.uk/Howweregulate/Innovation/EarlieraccesstomedicinesschemeEAMS/index.htm
New shortcut in UK
Maybe we don't need to wait for DF for CTIX to move forward. I saw reference to this on another IHUB board: http://www.mhra.gov.uk/Howweregulate/Innovation/EarlieraccesstomedicinesschemeEAMS/index.htm
Thioureidobutyronitrile
Has anyone actually heard the word Thioureidobutyronitrile pronounced by an expert? :)
The patients in the trials at DF are at death's door. Do we know if any have succumbed to their cancer, or if those who have dropped out have some other reason. Do we know the #s of survivors so far in the trials? Just to have survived says a lot for Kevetrin.
gh
The looming study of B is looking like a short term and inexpensive one. Even without significant new CTIX financing, if we get some cooperative medical institution (they should be easy to find, given Dr. M's and Leo's connections) to do the study if CTIX just provides the drug. This would be similar to MD Anderson's and U of Bologna's deals for the next studies of K. The institutions get the prestige of being pioneers; CTIX gets the study done inexpensively. The world gets new needed antibiotic quickly: WIN, WIN, WIN.
Your story reminds me of the big computer company in 1980 that had a sideline of building a small computer, no big deal. They just wanted to build the machine, and they made a little deal with a nothing little company to provide the operating system: just a $50K deal. I guess IBM didn't want to be in the software business, they just wanted to build the machines. They left the software chips on the table for Bill Gates to scoop up. How many thousands of 'Microsoft Millionaires' are there?
Really GREAT deals don't come along every day. And the public hardly ever gets a chance to participate. Leo's deal might not measure up to the Bill Gates deal, but some of us will wind up being 'CELLCEUTIX MILLIONAIRES' Thanks to Leo and Dr. Menon!
gh
My memory of the Aspire deal was that it was a WIN WIN. They got some cheap shares up front and CTIX got the flexibility of cash when we needed it. There was no exorbitant PIPE-like dilution. To my mind, a second iteration of that deal, tweaked to reflect the current situation, would be something to consider, pending a BIG deal with a deep pocket BIG pharma.